Research Analysts Offer Predictions for Danaher Q3 Earnings

Danaher Co. (NYSE:DHR - Free Report) - Equities researchers at William Blair dropped their Q3 2025 earnings per share (EPS) estimates for shares of Danaher in a research report issued to clients and investors on Tuesday, April 22nd. William Blair analyst M. Larew now forecasts that the conglomerate will post earnings per share of $1.88 for the quarter, down from their prior forecast of $1.94. The consensus estimate for Danaher's current full-year earnings is $7.63 per share. William Blair also issued estimates for Danaher's Q4 2025 earnings at $2.26 EPS, FY2025 earnings at $7.67 EPS and Q1 2026 earnings at $2.10 EPS.

Several other brokerages have also commented on DHR. UBS Group decreased their price target on Danaher from $275.00 to $240.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. Wells Fargo & Company decreased their price target on Danaher from $280.00 to $240.00 and set an "equal weight" rating on the stock in a research note on Thursday, January 30th. Raymond James reaffirmed a "market perform" rating on shares of Danaher in a research note on Monday, February 3rd. Robert W. Baird reduced their price objective on Danaher from $231.00 to $225.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 23rd. Finally, Stifel Nicolaus raised Danaher from a "hold" rating to a "buy" rating and set a $260.00 price objective on the stock in a research note on Friday, March 14th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, Danaher presently has a consensus rating of "Moderate Buy" and a consensus target price of $264.40.

Danaher Stock Performance

Shares of NYSE:DHR traded down $1.13 during trading on Friday, hitting $196.01. 2,715,127 shares of the stock were exchanged, compared to its average volume of 3,352,419. Danaher has a 1-year low of $171.00 and a 1-year high of $281.70. The company has a market capitalization of $140.28 billion, a price-to-earnings ratio of 37.12, a price-to-earnings-growth ratio of 2.66 and a beta of 0.86. The company's fifty day simple moving average is $200.87 and its 200-day simple moving average is $223.98. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping the consensus estimate of $1.62 by $0.26. Danaher had a return on equity of 10.82% and a net margin of 16.33%. The company had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.58 billion.

Institutional Trading of Danaher

A number of hedge funds and other institutional investors have recently made changes to their positions in DHR. Kentucky Retirement Systems Insurance Trust Fund raised its holdings in shares of Danaher by 11.6% in the 4th quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 21,233 shares of the conglomerate's stock valued at $4,874,000 after acquiring an additional 2,202 shares in the last quarter. ORG Partners LLC increased its position in shares of Danaher by 1,212.8% during the 4th quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate's stock valued at $636,000 after purchasing an additional 2,559 shares during the last quarter. Generate Investment Management Ltd bought a new position in shares of Danaher during the 4th quarter valued at about $8,044,000. Compass Capital Management Inc. increased its position in shares of Danaher by 4.8% during the 4th quarter. Compass Capital Management Inc. now owns 237,922 shares of the conglomerate's stock valued at $54,615,000 after purchasing an additional 10,994 shares during the last quarter. Finally, Channing Global Advisors LLC increased its position in shares of Danaher by 42.8% during the 4th quarter. Channing Global Advisors LLC now owns 5,666 shares of the conglomerate's stock valued at $1,301,000 after purchasing an additional 1,698 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Insider Activity

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the business's stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares of the company's stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 11.10% of the company's stock.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, April 25th. Stockholders of record on Friday, March 28th were issued a dividend of $0.32 per share. The ex-dividend date of this dividend was Friday, March 28th. This represents a $1.28 annualized dividend and a dividend yield of 0.65%. This is a positive change from Danaher's previous quarterly dividend of $0.27. Danaher's dividend payout ratio is currently 24.85%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.